The novel integrin-linked kinase inhibitor nilotinib suppresses cancer progression by promoting ubiquitylation of autoimmune regulator in oesophageal squamous cell carcinoma [0.03%]
一种新的整合素连接激酶抑制剂尼洛替尼通过促进自身免疫调节蛋白泛素化来抑制食管鳞癌的进展
Xiaoli Ma,Yu Wei,LeiYu Cao et al.
Xiaoli Ma et al.
Integrin-linked kinase (ILK) is a key oncogenic driver in oesophageal squamous cell carcinoma (ESCC). This study evaluated the antitumour effects of the novel ILK inhibitor Nilotinib and explored its downstream mechanisms. In vitro, TE-1 an...
Temozolomide-based therapy may remodel the tumor microenvironment and enhance immunotherapy sensitivity in advanced leiomyosarcoma [0.03%]
基于替莫唑胺的治疗可能会重塑肿瘤微环境并增强晚期平滑肌肉瘤免疫疗法敏感性
Huijing Tan,Zhuo Li,Jianguo Zhou et al.
Huijing Tan et al.
Leiomyosarcoma (LMS) is characterized by inherent resistance to immune checkpoint blockade, with no conclusive evidence supporting the efficacy of programmed death-1 (PD-1)/programmed death-ligand 1 inhibitor, and it is generally classified...
Response of undifferentiated and dedifferentiated endometrial cancer to pembrolizumab: a case report [0.03%]
派姆单抗治疗未分化及去分化的子宫内膜癌1例报告
Peter G Rose,Johanna Kelley,Aaron Petty et al.
Peter G Rose et al.
To report our experience with pembrolizumab in undifferentiated and dedifferentiated endometrial cancer. We performed an institutional review board-approved, retrospective study of computerized pharmacy records to identify all patients with...
Synergistic antitumor effect between Olaparib and Chidamide by regulation of MYBL2 in lung cancer [0.03%]
Olaparib联合Chidamide在肺癌中通过调节MYBL2的协同抗肿瘤作用
Lila Zhu,Zhi Ji,Xia Wang et al.
Lila Zhu et al.
Recently, various basic research and clinical studies have revealed the further potential of poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor Olaparib and histone deacetylase inhibitor Chidamide in lung cancer. However, no re...
Hyperthermia combined with intraperitoneal perfusion of drugs improves malignant ascites caused by gastrointestinal tumors by reshaping the tumor immune microenvironment [0.03%]
超高温联合腹腔灌注药物可通过重塑肿瘤免疫微环境来改善胃肠道肿瘤所致恶性腹水
Yongjian Zhang,Baomei Wang,Junhua Zhang et al.
Yongjian Zhang et al.
Malignant ascites treatment remains challenging. Hyperthermia is a promising adjunct to intraperitoneal therapies, but its mechanisms are unclear. We aimed to investigate whether combining hyperthermia with endostatin and cisplatin alleviat...
Remarkable efficacy of ivonescimab-based second-line therapy in advanced lung adenocarcinoma resistant to chemoimmunotherapy: a case report [0.03%]
伊沃西姆单抗在化疗免疫治疗后耐药的肺腺癌患者二线治疗中表现出良好的疗效：1例报告
Xuan Wang,Kunning Yang,Ping Yin
Xuan Wang
PD-1/PD-L1 inhibitors combined with chemotherapy are the current standard first-line treatment for advanced lung adenocarcinoma (LUAD). However, chemotherapy typically becomes the main therapeutic approach for subsequent treatment once the ...
Prochlorperazine inhibits the proliferation of hepatocellular carcinoma cells by promoting phosphorylation of β-catenin [0.03%]
普马克通过促进β-连环蛋白磷酸化抑制肝癌细胞增殖作用的研究
Yongjie Liang,Xiao Wang,Ruifeng Tian et al.
Yongjie Liang et al.
Hepatocellular carcinoma (HCC) is the most prevalent form of primary liver cancer and ranks as the third leading cause of cancer-related fatalities worldwide. Recently, prochlorperazine (PCZ), a synthetic antipsychotic medication, has gaine...
Successful treatment of hairy cell leukemia with TP53 abnormality using cladribine combined with low-dose rituximab: a case report and literature review [0.03%]
克拉屈滨联合小剂量利妥昔单抗治疗TP53异常的毛细胞白血病1例及文献复习
Zixin Chen,Lin Chen
Zixin Chen
Hairy cell leukemia (HCL) is a rare mature B-cell malignancy characterized by the BRAF V600E mutation. TP53 abnormalities in HCL are associated with poor response to standard therapies and a higher risk of relapse. We report an elderly male...
SENP3-mediated deSUMOylation stabilizes programmed death-ligand 1 to promote immune evasion in hepatocellular carcinoma [0.03%]
SENP3介导的脱SUMO化稳定程序性死亡配体1以促进肝细胞癌免疫逃逸
Bin Zhang,Jianbo Zheng,Yingan Zhao et al.
Bin Zhang et al.
Despite the clinical benefits of immune checkpoint blockade in hepatocellular carcinoma (HCC), therapeutic efficacy remains limited due to persistent immune evasion. SENP3, a SUMO2/3-specific protease sensitive to redox regulation, has emer...
Yuzhong Wang,Junfang Yuan,Shaowei Guo et al.
Yuzhong Wang et al.
Bladder cancer (BCa) patients frequently develop resistance to platinum-based therapies, particularly cisplatin. The link between chemoresistance and glycolysis has been well documented. Emerging evidence suggests that Rac family small GTPa...